Shares closed at $97.77 on Thursday as the S&P 500 fell 0.38% and the Dow Jones Industrial Average lost 0.63% in a broad market decline.
The stock finished 12.93% below its 52-week high of $112.29 reached on 7 January.
Among peers, Alnylam fell 2.34%, Bio-Techne rose 7.39% and BioMarin slipped 0.88%, while Incyte trading volume of 1.0 million was well below its 50-day average of 1.6 million.
Incyte's profits are soaring, but could a fatal drug trial in Europe secretly threaten its entire future?
Can Incyte’s promising new skin drug overcome the shadow cast by its troubled cancer treatment pipeline?